Answers are grounded in this paper and cite their sources.
Preclinical study demonstrates reduction of brain inflammation using an oral ASK1 inhibitor in tau transgenic mice, highlighting a viable therapeutic strategy for neurological disease.
Apoptosis signal-regulating kinase 1 (ASK1) is one of the key mediators of the cellular stress response that regulates inflammation and apoptosis. To probe the therapeutic value of modulating this pathway in preclinical models of neurological disease, we further optimized the profile of our previously reported inhibitor 3 . This effort led to the discovery of 32, a potent (cell IC 50 = 25 nM) and selective ASK1 inhibitor with suitable pharmacokinetic and brain penetration (rat Cl/Cl u = 1.6/56 L/h/kg and K p,uu = 0.46) for proof-of-pharmacology studies. Specifically, the ability of 32 to inhibit ASK1 in the central nervous system (CNS) was evaluated in a human tau transgenic (Tg4510) mouse model exhibiting elevated brain inflammation. In this study, transgenic animals treated with 32 (at 3, 10, and 30 mg/kg, BID/PO for 4 days) showed a robust reduction of inflammatory markers ( e.g., IL-1β) in the cortex, thus confirming inhibition of ASK1 in the CNS.
No takes yet. Share an insight, caveat, or question.
Jones et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: